MNG157
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.491
- KRAS_SIGNALING_DN+0.371
- ANGIOGENESIS+0.312
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.226
- G2M_CHECKPOINT+0.197
- PANCREAS_BETA_CELLS+0.184
- KRAS_SIGNALING_UP+0.182
- E2F_TARGETS+0.154
- APICAL_JUNCTION+0.124
- SPERMATOGENESIS+0.119
Top 10 suppressed
- DNA_REPAIR-0.480
- PROTEIN_SECRETION-0.456
- MYC_TARGETS_V1-0.435
- INTERFERON_ALPHA_RESPONSE-0.372
- UNFOLDED_PROTEIN_RESPONSE-0.330
- TGF_BETA_SIGNALING-0.328
- CHOLESTEROL_HOMEOSTASIS-0.319
- INTERFERON_GAMMA_RESPONSE-0.315
- WNT_BETA_CATENIN_SIGNALING-0.314
- ANDROGEN_RESPONSE-0.299
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG472 | — | — | 0.823 |
| 2 | SRR12202490 | — | — | 0.819 |
| 3 | MDT-AP-0317 | Med | Medulloblastoma | 0.816 |
| 4 | SRR26320080 | — | — | 0.801 |
| 5 | MDT-AP-0374 | Med | Medulloblastoma | 0.792 |
| 6 | SRR1516036 | — | — | 0.792 |
| 7 | MNG1093 | — | — | 0.789 |
| 8 | BS_44A3ES23 | Med | Medulloblastoma | 0.788 |
| 9 | MNG159 | — | — | 0.784 |
| 10 | SRR6013476 | — | cohortSQ1 | 0.782 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.491 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.371 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.312 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.226 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.197 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.184 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.182 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.154 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.124 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.119 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.113 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.106 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.092 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.076 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.073 | Idelalisib | — uncovered |
| COAGULATION | 0.062 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.043 | Temsirolimus | — uncovered |
| HYPOXIA | 0.042 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.030 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.029 | Inavolisib | — uncovered |